A subscription to JoVE is required to view this content. Sign in or start your free trial.

Method Article

Novel Atomic Force Microscopy Based Biopanning for Isolation of Morphology Specific Reagents against TDP-43 Variants in Amyotrophic Lateral Sclerosis

8.4K views

⸱

DOI:

10.3791/52584

⸱

February 12th, 2015

 ,  ,  ,  ,  , 

In This Article

Summary

Using atomic force microscopy in combination with biopanning technology we created a negative and positive biopanning system to acquire antibodies against disease-specific protein variants present in any biological material, even at low concentrations. We were successful in obtaining antibodies to TDP-43 protein variants involved in Amyotrophic Lateral Sclerosis.

Abstract

Because protein variants play critical roles in many diseases including TDP-43 in Amyotrophic Lateral Sclerosis (ALS), alpha-synuclein in Parkinson’s disease and beta-amyloid and tau in Alzheimer’s disease, it is critically important to develop morphology specific reagents that can selectively target these disease-specific protein variants to study the role of these variants in disease pathology and for potential diagnostic and therapeutic applications. We have developed novel atomic force microscopy (AFM) based biopanning techniques that enable isolation of reagents that selectively recognize disease-specific protein variants. There are two key phases involved in the process, the negative and positive panning phases. During the negative panning phase, phages that are reactive to off-target antigens are eliminated through multiple rounds of subtractive panning utilizing a series of carefully selected off-target antigens. A key feature in the negative panning phase is utilizing AFM imaging to monitor the process and confirm that all undesired phage particles are removed. For the positive panning phase, the target antigen of interest is fixed on a mica surface and bound phages are eluted and screened to identify phages that selectively bind the target antigen. The target protein variant does not need to be purified providing the appropriate negative panning controls have been used. Even target protein variants that are only present at very low concentrations in complex biological material can be utilized in the positive panning step. Through application of this technology, we acquired antibodies to protein variants of TDP-43 that are selectively found in human ALS brain tissue. We expect that this protocol should be applicable to generating reagents that selectively bind protein variants present in a wide variety of different biological processes and diseases.

Introduction

The presence of protein variants has been implicated as a factor in the progression of many diseases including neurodegenerative diseases such as Alzheimer’s, Parkinson’s, ALS and Frontotemporal Dementia (FTD)1,2,3,4,5,6,7,8,9,10,11. Oligomeric forms of the proteins beta-amyloid and alpha-synuclein are thought to be the toxic species responsible for Alzheimer’s and Parkinson’s, respectively2,3,4,5. Aggregates of the TAR DNA-binding protein 43 (TDP-43) have been linked to ALS and FTD12,13,14. Therefore reagents such as antibodies that can selectively target the different protein variants can be powerful tools to ....

Access restricted. Please log in or start a trial to view this content.

Protocol

1. Phage Production

  1. Perform all phage production and biopanning processes in a biosafety cabinet. Produce phages particles from the different libraries (Tomlinson I and J libraries and Sheets library21) for the biopanning process using the manufacturer’s instructions (http://www.lifesciences.sourcebioscience.com/media/143421/tomlinsonij.pdf).
    NOTE: We use multiple libraries in our panning process to increase the diversity of the antibodies available.
  2. Briefly, culture bacteria stocks of the three libraries in 200 ml of 2xYT containing 1% glucose and 100 μg/ml of ampicillin on a shaker at 37 °C until OD600

Access restricted. Please log in or start a trial to view this content.

Results

In Figure 1, the schematic demonstrates the negative panning process by which we removed phage binding off-target antigens from our library using immunotubes. We initially started with BSA since this is a common blocking agent and any phage that would react nonspecifically with this target would be problematic in future immunoassays. Next, we removed binders to aggregated alpha-synuclein to eliminate phage that are reactive with generic structures of aggregated proteins (i.e., an antibody that w.......

Access restricted. Please log in or start a trial to view this content.

Discussion

Protein variants have been shown to be involved in the progression of many neurodegenerative diseases such as Alzheimer’s, Parkinson’s, ALS and FTD1,2,3,4,5,6,7,8,9,10,11. Isolation of antibodies that can selectively recognize these different protein variant targets can be effective reagents to study, diagnose and potentially treat such ailments. To generate such variant specific antibodies we have developed a novel biopanning process that utilizes atomic force microscopy to monitor the progress .......

Access restricted. Please log in or start a trial to view this content.

Disclosures

The authors have nothing to disclose.

Acknowledgements

This research was supported by a grant from NIH: R21AG042066. We would like to thank Philip Schulz for his contributions in creating the screen capture videos.

....

Access restricted. Please log in or start a trial to view this content.

Materials

List of materials used in this article
NameCompanyCatalog NumberComments
Tomlinson I and J LibrariesMRC (Cambridge, England)
Sheets LibraryMRC (Cambridge, England)
2xYTBD Sciences244020
GlucoseAmresco0188-2.5KG
AmpicillinAmresco0339-25GIrritant
KM13 Helper PhageMRC (Cambridge, England)
KanamycinOmniPur5880Irritant
Polyethylene Glycol 8000OmniPur6510Irritant
Sodium ChlorideMacron7647-14-5
Sodium Phosphate DibasicAmresco0404-1KGIrritant
Potassium ChlorideEMDPX1405-1Irritant
Potassium Phosphate MonobasicAmresco0781-500GIrritant
TG1 CellsMRC (Cambridge, England)
Luria-Bertani AgarEMD1.10283.0500
Bovine Serum AlbuminAmresco0332-100G
STEN bufferCrystalgen Inc.33429775
ImmunotubesThermo Scientific470319
MicaSpruce Pine Mica24365
Tween 20EMD
TrypsinSigmaT-0303Irritant
TriethylamineSigmaT-0886Flammable
GlycerolAmresco0854-1LIrritant
DNA Plasmid Prep Kitqiagen27106Irritant
Non-Fat Milk PowderCarnation
96-Well High Binding ELISA PlateCostar3590
Anti-M13 HRPGE Healthcare Life Sciences27-9421-01
ELISA Femto Chemiluminescence Substrate KitThermo Scientific37074
Anti-TDP 43 Polyclonal AntibodyProteinTech10782-2-AP
A/G Agarose BeadsSanta Cruz Biotechnologysc-2003
HB 2151 CellsMRC (Cambridge, England)
IsopropylthiogalactosideTeknova13325
9e10 HRPSanta Cruz Biotechnologysc-40
Nitrocellulose MembraneBiorad162-0115Flammable
CentrifugeThermo ScientificSorvall RC 6+
Nanoscope IIIa Atomic Force MicroscopeVeeco
AFM ProbesVistaProbesT300R-10

References

  1. Hedieh, B., Sharareh, E., Philip, S., Michael, R. S. Isolating recombinant antibodies against specific protein morphologies using atomic force microscopy and phage display technologies. Protein Engineering Design and Selection. 19, 497-502 (2006).
  2. Emadi, S., Barkhordarian, H., Wang, M. S., Schulz, P., Sierks, M. R.

Access restricted. Please log in or start a trial to view this content.

Reprints and Permissions

Explore More Articles

Biopanning TechniqueNegative Panning PhasePositive Panning PhasePhage Library ScreeningAFM Imaging VerificationMica Surface BindingSelective Reagent Isolation